T Cell Profiling in Patients with Multiple Sclerosis

NCT ID: NCT04789551

Last Updated: 2025-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this research study is to to learn more about the body's immune response in patients with multiple sclerosis (MS). In MS, the body's immune cells mistakenly attack an important part of the nerves of the brain and spinal cord. The immune cells responsible for attacking the nerves in MS patients is primarily the T cells. A marker was recently discovered that might specifically identify these damaging T cells from all other T cells in the body. Understanding which T cells cause the damage in MS patients and understanding more about these specific T cells may help doctors better understand how MS occurs and could possibly prevent MS in the future.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple Sclerosis Stable Conditions

Multiple sclerosis patients presenting for a routine clinic visit.

Blood Sample

Intervention Type OTHER

a blood sample will be collected

Multiple Sclerosis Acute Flare Up

Multiple sclerosis patients admitted to the hospital with acute symptoms.

Blood Sample

Intervention Type OTHER

a blood sample will be collected

Control patients

Patients without any immunological diseases who present for elective surgery.

Blood Sample

Intervention Type OTHER

a blood sample will be collected

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Sample

a blood sample will be collected

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-diagnosis of multiple sclerosis and present to the neurology clinic for a regular checkup or are admitted to the inpatient floor with acute symptoms.

Exclusion Criteria

* Have an active infection
* Take T cell modulating drugs

* Have an active infection.
Minimum Eligible Age

13 Years

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Children's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lifei Hou

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boston Children's Hopsital

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lifei Hou, PhD

Role: CONTACT

617-713-8154

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lifei Hou, PhD

Role: primary

Koichi Yuki, MD

Role: backup

617-355-6225

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB-P00037843

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Immunodeficiency in MS
NCT04447937 UNKNOWN
T-Cell Vaccination in Multiple Sclerosis (MS)
NCT00220428 UNKNOWN PHASE1/PHASE2
Mesenchymal Stem Cells for Multiple Sclerosis
NCT01730547 COMPLETED PHASE1/PHASE2
ATX-MS-1467 in Multiple Sclerosis
NCT01973491 COMPLETED PHASE2